Differentiation therapy has distinct advantages over conventional therapeutic strategies
Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “” Company”, a biopharmaceutical company developing new cancer treatments for patients with recurrent and metastatic cancer, today announced a new way to stop the cancer by inducing a process called “cell differentiation”. differentiation therapy has advantages over conventional therapeutic strategies Differentiation therapy does not target cell death, so the patient’s healthy cells will not be compromised, unlike chemotherapeutic drugs or gamma irradiation.
First, most people understand that cancer develops when cells in the body begin to divide rapidly and uncontrollably, with the ability to migrate from one location and spread to distant sites. A cell becomes cancerous when it becomes undifferentiated. Essentially, the cell forgets to do its job and invests all its energy in proliferating. Unlike normal cells, cancer cells multiply, but do not differentiate. Therefore, most current cancer therapies work by taking advantage of the uncontrolled proliferation of cancer cells and killing these cells by targeting the cell division machinery. These therapies are effective, but also affect healthy cells, especially those with a high cell renewal rate, thus inducing adverse effects.
Conversely, differentiation therapy induces cancer cells into the pathway of terminal differentiation (fully differentiated) and eventual senescence (i.e. loss of division and growth of a cell ). Differentiation therapy not only works against cancer cells, but can also transform cancer stem cells (undifferentiated cells) into fully differentiated (i.e. normal) cells.
But what lesson can we learn from our own bodies? Are there natural elements in our body that could help us fight cancer? In fact, yes, there are enzymes, which are natural proteins that stimulate and speed up biological reactions in the body. In particular the enzymes secreted by the pancreas which are essential for the digestion of proteins and fats. Over 100 years ago, Professor John Beard of the University of Edinburgh first proposed that pancreatic enzymes represent the body’s main defense against cancer and would be useful as a cancer treatment. Since then, several scientists have endorsed Beard’s hypothesis with encouraging patient treatment data.
Since 2007, Propanc has been developing a long-term therapy based on a pancreatic proenzyme formulation to prevent tumor recurrence and metastasis, the leading cause of cancer patient death. PRP is a new patented formulation consisting of two proenzymes blended in a synergistic ratio. After extensive laboratory research and a limited number of human tests, Propanc has evidence that PRP reduces cancer cell growth by promoting cell differentiation, improves cell adhesion (cell-to-cell contact) and suppresses the progression of metastases, has no serious side effects and improves patient survival. .
“Differentiation therapy may be the best way to stop cancer because it’s a unique approach to targeting cancer cells while leaving healthy cells alone, reducing side effects while successfully preventing the return and spread of cancer,” said Dr. Julian Kenyon, Scientific Director of Propanc’ “We believe that PRP complements existing treatment methods and we look forward to our planned early-stage clinical development of PRP in advanced cancer patients with solid tumors such as pancreatic, ovarian and colorectal cancers.”
PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from the bovine pancreas administered by intravenous injection. A synergistic ratio of 1:6 inhibits the growth of most tumor cells. Examples include kidney, ovarian, breast, brain, prostate, colorectal, lung, liver, uterine, and skin cancers.
About Propanc Biopharma, Inc.
Propanc Biopharma, Inc. (the “Company”) is developing a novel approach to prevent recurrence and metastasis of solid tumors using pancreatic proenzymes that target and eradicate cancer stem cells in patients with pancreatic, ovary and colorectal For more information, visit www.propanc.com.
The company’s new proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, specifically enzymes secreted by the pancreas. These pancreatic enzymes may represent the body’s main defense against cancer.
To view the company’s “Mechanism of Action” video on its lead cancer product candidate, PRP, please click on the following link: http://www.propanc.com/news-media/video
All statements other than statements of historical facts contained in this press release are “forward-looking statements”,” which can often, but not always, be identified by the use of words such as “may,” “could,” “will,” “probably result,” “would,” “should,” “estimate,” “plan, ” “plan,” “forecast,” “intention,” “expect,” “anticipate,” “believe,” “seek,” “continue,” “target” or the negative of these terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements. the Company’s ability to continue operations in the absence of new debt or equity financing; the Company’s current dependence on significant debt financing that it is unable to repay in cash; the capacity of the So company to successfully address material weaknesses in its internal controls; the Company’s ability to achieve research and development milestones as planned and within proposed budgets; the Company’s ability to control costs; the Company’s ability to obtain adequate new financing on reasonable terms; the Company’s ability to successfully initiate and complete clinical trials and its ability to successfully develop PRP, its lead product candidate; the Company’s ability to obtain and maintain patent protection; the Company’s ability to recruit employees and directors with accounting and financial expertise; the company’s reliance on third parties for services; the company’s dependence on key management; the impact of government regulations, including FDA regulations; the impact of any future litigation; the availability of capital; changes in economic conditions, competition; and other risks, including, but not limited to, those described in the Company’s periodic reports filed with the Securities and Exchange Commission and available on its website at http://www.sec .gov. These forward-looking statements speak only as of the date hereof, and the Company disclaims any obligation to update these statements, except as required by law.